pre-IPO PHARMA

COMPANY OVERVIEW

Diamond Therapeutics is a drug development company based in Toronto, Ontario. Our mission is to develop new and better therapies for mental health conditions by unlocking the promise of psychedelic compounds. Diamond is focused on sub-perceptual, non-hallucinogenic treatments that hold potential for use across a broad patient cohort —maximizing the positive impact better drugs can have on global mental health.


LOCATION


THERAPEUTIC AREAS


WEBSITE

https://www.diamondthera.com


CAREER WEBSITE

None


SOCIAL MEDIA


INVESTORS


PRESS RELEASES


Apr 4, 2023

First Avenue Ventures Life Science Fund I Invests in Diamond Therapeutics to Accelerate Innovation in Mental Health


Mar 21, 2023

Diamond Therapeutics Announces FDA-authorized Clinical Trial of Low-Dose Psilocybin in Collaboration with University of Alabama at Birmingham


Jan 24, 2023

Diamond Therapeutics Announces Health Canada Approval of Phase 2 Clinical Trial with Low-Dose Psilocybin


Dec 7, 2022

Diamond Therapeutics completes Phase I clinical study of low-dose psilocybin in healthy human subjects


Mar 29, 2022

Diamond Therapeutics Achieves Last Patient Last Visit in Clinical Trial of Low-Dose Psilocybin


For More Press Releases


Google Analytics Alternative